Nothing can reach the brain damage of Hunter syndrome
The core idea stands, but key numbers or details have changed.
TaughtIn Hunter syndrome, a missing enzyme lets sugary molecules pile up in cells throughout the body and the brain. Enzyme replacement can help the body, but the replacement enzyme cannot cross the blood-brain barrier, so the cognitive decline is untouchable.
NowOn 25 March 2026 the FDA approved Avlayah (tividenofusp alfa), an enzyme replacement engineered to cross the blood-brain barrier: the first treatment for Hunter syndrome aimed at its neurological damage, and the first FDA approval for the disease in nearly twenty years.
What actually happened
The blood-brain barrier is the reason so many enzyme therapies stop at the neck: the molecules are too big to pass. Avlayah is built as a kind of molecular Trojan horse: the therapeutic enzyme fused to a piece that binds a transporter the barrier uses to ferry things across, carrying the enzyme into the brain with it. That 'transport vehicle' design is a genuinely new class of biologic, not just a new drug.
The caution is that it was granted accelerated approval, based largely on lowering a biomarker of the stored sugars in spinal fluid, with confirmatory trials ongoing, and it must be started before advanced neurological damage sets in. So this is 'updated': a devastating disease still is one. But the specific wall taught to families, that the brain in Hunter syndrome is simply beyond the reach of any drug, has a first crack in it.
Newsletter
Get new weekly revisions
Sources
- Denali Therapeutics: FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter Syndrome (MPS II)investors.denalitherapeutics.com
- Fierce Pharma: FDA approves Denali's Hunter syndrome drugfiercepharma.com
Who was taught this
Still standard through 2026, so anyone who finished school between 1950 and 2026 learned the earlier version.